Laborie Completes Deal for Urotronic, Maker of the Optilume DCB

Laborie Medical Technologies revealed that it completed its acquisition deal for Urotronic, developer of the Optilume drug-coated balloon (DCB) used to treat urethral strictures andn benign prostatic hyperplasia (BPH) or enlarged prostate conditions.
 
The up to $600 million dollar deal was first announced in early September.
 
Optilume DCB is a novel, minimally invasive surgical therapy that pairs mechanical dilation with paclitaxel delivery to treatlower urinary tract symptoms that are secondary to urological stricture or BPH. Optiluma products hold both U.S. Food and Drug Administration (FDA) approval and CE mark clearance.
 
Laborie said Urotronic and its employees will be integrated into the Laborie business as part of the deal, bolstering its Urology workforce and portfolio of technologies.
 
“We are delighted to welcome the Urotronic team to Laborie, and we look forward to working together in our mission to deliver innovative technologies in the Interventional Urology space that preserve and restore human dignity,” Laborie president and CEO Michael Frazzette told the press.
 
“Joining the Laborie team is an exciting new chapter for Urotronic,” added Urotronic president and CEO David Perry. “Over the last several years, we have seen our partnership develop because we are united on a goal to improve the standard of care for patients and commercialize Optilume products on a global stage.”